Novo Nordisk snatches Dicerna
Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1379 entries already.
Entries by Thomas Gabrielczyk
LSP and EQT merge to create top-10 investment firm
/in News/by Thomas GabrielczykLife Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Novartis inks US-$1.3bn deal with Dunad Therapeutics
/in News/by Thomas GabrielczykDunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies.
Agomab Therapeutics to acquire Origo Biopharma
/in News/by Thomas GabrielczykBelgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
Sofinnova Capital X Fund closed at 472m
/in News/by Thomas GabrielczykParis-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
Curevac withdraws MAA of CVnCoV
/in News/by Thomas GabrielczykGerman CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.
Delivering on Europe´s Green Deal EFIB 2021 in Vienna
/in News/by Thomas GabrielczykLeading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, […]
COVID-19 immunisation set to get FDA EUA
/in News/by Thomas GabrielczykPharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its antibody duo AZD7442.
BioNTech investigates cancer vaccine BNT122 in Phase II trial
/in News/by Thomas GabrielczykBionTech SE, which has been very successful in the field of corona vaccines, is starting phase II tests with its colorectal cancer candidate BNT122.
Advent France Biotechnology launches 86m fund
/in News/by Thomas GabrielczykAdvent France Biotechnologys has launched a second biotech seed fund with a first close at 86m. Since 2017, the French state fund has financed 15 startups in France, Spain, Belgium […]